George Yaghmour MD FACP
Hematologic Oncology
Associate Director of USC Norris Blood and Marrow Transplant Program at University of Southern California
Join to View Full Profile
1441 Eastlake AveLos Angeles, CA 90089
Phone+1 800-872-2273
Fax+1 323-865-3868
Dr. Yaghmour is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. George Yaghmour is a hematologist in Los Angeles, CA and is affiliated with multiple hospitals in the area, including Keck Hospital of USC and USC Norris Comprehensive Cancer Center. He received his medical degree from University of Aleppo Faculty of Medicine and has been in practice 11 years. He specializes in hematologic oncology and is experienced in leukemia,lymphoma, Multiple Myeloma, Rare Hematologic disease, Bone marrow failure, and cellular therapy, with advanced skills in stem cell transplantation. He has more than 30 publications and over 150 citings.
Education & Training
University of Aleppo Faculty of MedicineClass of 2008
Wayne State University School of MedicineResidency, Internal Medicine
Certifications & Licensure
CA State Medical License 2016 - 2027
TN State Medical License 2015 - 2018
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy.Hannah Lust, Liora M Schultz, Soyang Kwon, Gregory W Roloff, Ibrahim Aldoss
Blood Advances. 2025-03-24 - Combination of 2-Chlorodeoxyadenosine, Cytarabine, and Granulocyte Colony-Stimulating Factor and Venetoclax in a Case of Acute Myelogenous Leukemia.Ella Prebel Jackert, Karrune Woan, Preet Chaudhary, George Yaghmour, Abdullah Ladha
Journal of Medical Cases. 2025-03-01 - Randomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia.Athalia Rachel Pyzer, Laura W Dillon, Elad Sharon, Theodore G Karrison, Yuanyuan Zha
Blood Advances. 2025-02-10
Press Mentions
Combo Treatment Sans Chemotherapy Effective for Ph+ ALL ElderlyDecember 12th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
